FI126711B - Bedömning av en hälsorisk i samband med serotoninbrist - Google Patents

Bedömning av en hälsorisk i samband med serotoninbrist Download PDF

Info

Publication number
FI126711B
FI126711B FI20116007A FI20116007A FI126711B FI 126711 B FI126711 B FI 126711B FI 20116007 A FI20116007 A FI 20116007A FI 20116007 A FI20116007 A FI 20116007A FI 126711 B FI126711 B FI 126711B
Authority
FI
Finland
Prior art keywords
bifidobacteria
serotonin
clostridia
health risk
relative proportion
Prior art date
Application number
FI20116007A
Other languages
English (en)
Finnish (fi)
Other versions
FI20116007A (sv
FI20116007A0 (sv
Inventor
Annika Mäyrä-Mäkinen
Eveliina Munukka
Original Assignee
Gut Guide Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gut Guide Oy filed Critical Gut Guide Oy
Priority to FI20116007A priority Critical patent/FI126711B/sv
Publication of FI20116007A0 publication Critical patent/FI20116007A0/sv
Priority to US14/350,941 priority patent/US10087480B2/en
Priority to EP12840489.4A priority patent/EP2766027B1/en
Priority to PCT/FI2012/050978 priority patent/WO2013054001A1/en
Publication of FI20116007A publication Critical patent/FI20116007A/sv
Application granted granted Critical
Publication of FI126711B publication Critical patent/FI126711B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)

Claims (2)

1. Menetelmä serotoniinivajeeseen liittyvän terveysriskin arvioimiseksi, tunnettu siitä, että menetelmässä määritetään in vitro bifidobaktee-rien osuus suoliston Erec-ryhmän klostrideihin nähden, jolloin bifidobakteerien mainittu osuus korreloi negatiivisesti terveysriskin kanssa. Patentkrav
1. Förfarande för bedömning av en hälsorisk i samband med sero-toninbrist, kännetecknat av att i förfarandet fastställs i n vitro andelen bi-fidobakterier i förhållande till klostridier i Erec-gruppen i mag-tarmkanalen, varvid bifidobakteriernas nämnda andel korrelerar negativt med hälsorisken.
FI20116007A 2011-10-12 2011-10-12 Bedömning av en hälsorisk i samband med serotoninbrist FI126711B (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FI20116007A FI126711B (sv) 2011-10-12 2011-10-12 Bedömning av en hälsorisk i samband med serotoninbrist
US14/350,941 US10087480B2 (en) 2011-10-12 2012-10-12 Raising and diagnosing of serotonin level
EP12840489.4A EP2766027B1 (en) 2011-10-12 2012-10-12 Raising and diagnosing of serotonin level
PCT/FI2012/050978 WO2013054001A1 (en) 2011-10-12 2012-10-12 Raising and diagnosing of serotonin level

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20116007A FI126711B (sv) 2011-10-12 2011-10-12 Bedömning av en hälsorisk i samband med serotoninbrist

Publications (3)

Publication Number Publication Date
FI20116007A0 FI20116007A0 (sv) 2011-10-12
FI20116007A FI20116007A (sv) 2013-04-13
FI126711B true FI126711B (sv) 2017-04-13

Family

ID=44883675

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20116007A FI126711B (sv) 2011-10-12 2011-10-12 Bedömning av en hälsorisk i samband med serotoninbrist

Country Status (4)

Country Link
US (1) US10087480B2 (sv)
EP (1) EP2766027B1 (sv)
FI (1) FI126711B (sv)
WO (1) WO2013054001A1 (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150105651A1 (en) * 2013-10-16 2015-04-16 ZBH Enterprises, LLC Systems and methods for mri-based health management
WO2016036615A1 (en) * 2014-09-03 2016-03-10 California Institute Of Technology Microbe-based modulation of serotonin biosynthesis
CN104392086B (zh) * 2014-09-09 2017-11-24 广东工业大学 一种基于皮尔逊秩次变量相关系数的信号检测电路及方法
CA3006044A1 (en) * 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
JP6353478B2 (ja) * 2016-03-28 2018-07-04 日清食品ホールディングス株式会社 セロトニン分泌促進能力を有するビフィズス菌
US11224605B2 (en) 2016-05-19 2022-01-18 Glycom A/S Synthetic composition
DK3600364T3 (da) 2017-06-14 2020-08-31 4D Pharma Res Ltd Sammensætninger omfattende en bakteriestamme af slægten megasphaera og anvendelser deraf
US10941433B2 (en) 2017-06-15 2021-03-09 Iowa State University Research Foundation, Inc. Neurotransmitter transport in probiotics
WO2019060661A1 (en) 2017-09-22 2019-03-28 Iowa State University Research Foundation, Inc. PROBIOTIC COMPOSITIONS FOR THE PRODUCTION OF DOPAMINE
AU2018361591A1 (en) * 2017-11-02 2020-06-18 Gc Corporation Intraoral examination method using information on bacterial group related to clinical indexes
TW202038979A (zh) * 2018-12-12 2020-11-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
US20220249526A1 (en) * 2019-06-12 2022-08-11 Glycom A/S Human milk oligosaccharides and compositions thereof for use in preventing, managing or treating symptoms related to migraine
CA3144072A1 (en) * 2019-06-27 2020-12-30 Holobiome, Inc. Therapeutic compositions and methods of using serotonin modulating microbiome-based interventions to treat serotonin-related diseases or disorders
IT201900011193A1 (it) * 2019-07-08 2021-01-08 Sofar Spa Ceppo di batteri Bifidobacterium bifidum, sue composizioni e relativi usi
EP3897836B1 (en) * 2019-11-08 2023-08-16 Biogaia AB Serotonin producing bacteria
CN114947134B (zh) * 2022-05-06 2024-01-26 河北一然生物科技股份有限公司 嗜热链球菌s131在改善肠道健康及调节肠道菌群中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2826808B2 (ja) * 1995-07-14 1998-11-18 カルピス株式会社 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
FI112504B (sv) 2002-08-07 2003-12-15 Cyflo Oy Förfarande för identifiering av bakterier
US20040265279A1 (en) 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
BRPI0514903A (pt) * 2004-09-03 2008-06-24 Hansens Lab proteìnas vegetais ou leite fermentado compreendendo ligando de receptor e uso dos mesmos
EP1974734A1 (en) 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
US8669267B2 (en) * 2008-08-21 2014-03-11 Suntory Holdings Limited Pharmaceutical, food or beverage having inhibitory activity on serotonin transporter
WO2011058535A1 (en) 2009-11-11 2011-05-19 Alimentary Health Limited Probiotic bifidobacterium strain
BR112012011294B1 (pt) * 2009-11-12 2018-03-20 Nestec S.A. Composição nutricional para administração a um indivíduo
KR101143997B1 (ko) 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법

Also Published As

Publication number Publication date
EP2766027A4 (en) 2015-03-25
FI20116007A (sv) 2013-04-13
US20140301995A1 (en) 2014-10-09
EP2766027B1 (en) 2019-09-04
WO2013054001A1 (en) 2013-04-18
US10087480B2 (en) 2018-10-02
EP2766027A1 (en) 2014-08-20
FI20116007A0 (sv) 2011-10-12

Similar Documents

Publication Publication Date Title
FI126711B (sv) Bedömning av en hälsorisk i samband med serotoninbrist
Kong et al. Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet
Wegierska et al. The connection between physical exercise and gut microbiota: implications for competitive sports athletes
Sanz et al. Understanding the role of gut microbes and probiotics in obesity: how far are we?
EP2766026B1 (en) Prevention and diagnosis of visceral fat
Nagata et al. The effects of the Lactobacillus casei strain on obesity in children: a pilot study
Eor et al. Laxative effect of probiotic chocolate on loperamide-induced constipation in rats
AU2016214420B2 (en) Probiotic composition at least comprising Bifidobacterium bifidum W23 and capable of controlling intestinal barrier function
TWI572354B (zh) 抑制發炎之組成物
JP6101818B2 (ja) 体重増加及びインスリン抵抗性を治療又は予防するためのビフィドバクテリウムアニマリスの使用
AU2017274416A1 (en) Compositions and methods for treating inflammatory bowel diseases (IBDS) and other disorders
Darbandi et al. The effects of probiotics on reducing the colorectal cancer surgery complications: a periodic review during 2007–2017
EP2337569A2 (en) Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
Bjerg et al. Lactobacillus paracasei subsp paracasei L. casei W8 suppresses energy intake acutely
EP3164143B1 (en) Microbiomarker for celiac disease and a related product
Ziemons et al. Gut microbiota and metabolic aspects of cancer cachexia
EP3134543B1 (en) Method for diagnosing hepatic fibrosis
Liaqat et al. Role of modified diet and gut microbiota in metabolic endotoxemia in mice
Bedani et al. Potential benefits of probiotics, prebiotics, and synbiotics on the intestinal microbiota of the elderly
Hasegawa et al. Yogurt Supplementation Attenuates Insulin Resistance in Obese Mice by Reducing Metabolic Endotoxemia and Inflammation
RU2788397C1 (ru) Способ лечения затяжного течения кишечной инфекции кампилобактериозной этиологии у детей раннего возраста
Murray et al. The Influence of Gut Microbiota in Psychosis
AU2018361704A1 (en) Diagnostic and therapeutic methods for type 2 diabetes
Freitas et al. Effect of a probiotic fermented milk supplementation on behavior and sleep
Sauceda Development of Protocols to Test the Ability of Akkermansia muciniphila to Rescue Gut Barrier Integrity and Metabolize Azoxymethane

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: GUT GUIDE OY

FG Patent granted

Ref document number: 126711

Country of ref document: FI

Kind code of ref document: B